FDA Clears Interventional Spine’s Lateral Opticage Expandable Interbody Fusion Device

The Lateral approach adds to the Interventional Spine® family of Opticage™ Expandable Interbody Fusion Devices previously cleared for TLIF

Interventional Spine®, Inc., has announced FDA clearance of its Lateral Opticage™ Expandable Intervertebral Body Fusion Device.

Background

This device joins the Interventional Spine® family of Opticage™ Expandable Interbody Fusion Devices previously cleared for TLIF earlier this year, and used with the Company’s PerX360 System™.

The Opticage™ Expandable Intervertebral Body Fusion Device is a lumbar intervertebral body fusion device and is indicated for use with autogenous bone graft in patients with degenerative disc disease (DDD) at one or two contiguous levels from L2-S1. The Opticage™ Expandable Interbody Fusion Device can be implanted via posterior, transforaminal or lateral approach.

Company comments

Mr. Walter A. Cuevas, Chief Executive Officer of Interventional Spine said: “With this milestone, Interventional Spine continues to lead the spine market in providing the most innovative solutions for surgeons, which in the end, benefit patients. This new indication for the Opticage™ Expandable Interbody Fusion Devices broadens the application of Interventional Spine’s technology to significantly more patients.”

Source: Interventional Spine, Inc., PR Newswire

published: November 25, 2014 in: Approval/Clearance, Spine

Leave a Reply

Your email address will not be published. Required fields are marked *

Most read

Latest

^